VR Logo

Qualigen Therapeutics Inc. (QLGN) download report


Healthcare | Biotechnology & Pharma Research

Qualigen Therapeutics Inc. (QLGN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases.

IPO Date: 24-Jun-2015

Chairman & CEO: Mr. Michael S. Poirier

Pres, Chief Strategy Officer & Director: Ms. Amy S. Broidrick

Listing: NASDAQ: QLGN

Country: United States

Headquarters: Carlsbad, CA

Website: https://www.qualigeninc.com

Key Facts

Market cap: $20.25 Mln

Revenue (TTM): $5.54 Mln

Earnings (TTM): $-18.54 Mln

Cash: $13.61 Mln

Total Debt: $1.64 Mln

Insider's Holding: 11.73%

Liquidity: Low

52 Week range: $0.45 - 3.12

Shares outstanding: 38,795,500

7 Years Aggregate:

  • CFO: $-66.50 Mln
  • EBITDA: $-82.84 Mln
  • Net Profit: $-91.14 Mln

Stock Performance

Time Period Qualigen Therapeutics (QLGN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-51.21-8.07-18.78
1 month-4.22-3.97-8.00
3 months-20.91-11.65-13.65
1 Year-73.772.03-17.19
3 Years-73.0810.306.10
5 Years-67.2011.405.87
10 Years--11.869.84
As on 01-Jul-2022 *As on 05-Jul-2022
Year Qualigen Therapeutics (QLGN) S&P Small-Cap 600 S&P BSE Sensex
2021-64.4525.2721.99
2020-28.729.5715.75
2019-71.8520.8614.38
2018-81.62-9.705.87
2017-87.8511.7327.91
201659.4124.741.95